Clinical Trial Detail

NCT ID NCT02327078
Title A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Incyte Corporation
Indications

non-small cell lung carcinoma

head and neck squamous cell carcinoma

diffuse large B-cell lymphoma

non-Hodgkin lymphoma

glioblastoma multiforme

ovarian cancer

colorectal cancer

Hodgkin's lymphoma

melanoma

Therapies

INCB024360 + Nivolumab

Age Groups: adult

No variant requirements are available.